drugset / Trial / NCT03982862

Botulinum Toxins Intralesional Injection for Scar Pain

NCT03982862

Phase 4 Unknown 20 enrolled Kaohsiung Medical University
RandomizedCrossoverSingle-blindTreatment

Summary

Botulinum toxins has been approved by the FDA to treat chronic migraine. Botox had been shown to inhibiting the release of inflammatory mediators and peripheral neurotransmitters from sensory nerve to treat neuropathic pain. In the clinical practice, botox indeed effect in scar pain. However, investigators need well controlled study to prove this finding and assess the improvement of scar appearance.

Timeline

Start
2018-07-30
Primary completion
2019-06-30
Completion
2019-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 4 iu Other
Subject Triamcinolone Other / unclassified 4 mg Other
Background Lidocaine Other / unclassified 0.1 ml Other

Indications